Professionals

AAOMS 2022 Position Paper update on Medication Related Osteonecrosis of the Jaw

by Jill Meyer-Lippert May 14, 2022

AAOMS 2022 Position Paper update on Medication Related Osteonecrosis of the Jaw

Read the full update by clicking on the image below

Posted in Antiangiogenisis, Avastin, Bisphosphonates, Cancer, denonsumab, dental, Dental Oncology, medication-related osteonecrosis of the jaw, MRONJ, oncology, oral care, Oral Health, Oral Hygiene, Osteonecrosis, prevention, survivorship

Read more

Risks of medication-related osteonecrosis of the jaw in cancer patients (RDH Magazine)

by Jill Meyer-Lippert April 01, 2021

Risks of medication-related osteonecrosis of the jaw in cancer patients (RDH Magazine)

Click the image below to read, "Risks of medication-related osteonecrosis of the jaw in cancer patients" in the April 2021 edition of RDH Magazine ...

Posted in Antiangiogenisis, Avastin, Bisphosphonates, Cancer, denonsumab, dental, Dental Oncology, Dry Mouth, infection, medication-related osteonecrosis of the jaw, MRONJ, oncology, oral care, Oral Health, Oral Hygiene, Osteonecrosis, prevention, Side Effect Support, Side Effects, survivorship, targeted therapies, tooth decay

Read more

Beyond Bisphosphonates – A Closer Look at MRONJ and Cancer Therapy

by Jill Meyer-Lippert August 07, 2015

In 2014, the American Academy of Oral and Maxillofacial Surgeons released a position paper about medication–related osteonecrosis of the jaw (MRONJ...

Posted in Antiangiogenisis, Avastin, Bisphosphonates, Cancer, Dental Oncology, medication-related osteonecrosis of the jaw, MRONJ, Oral Cancer, Oral Health, Side Effects, Sutent, Tyrosine Kinase Inhibitor

Read more